Amgen (AMGN) Q1 2023: 14% Volume Growth Signals Durable Global Demand and Pipeline Leverage
Amgen’s first quarter showcased robust 14% volume growth across its portfolio, underscoring resilient demand and effective execution even as reported revenue was pressured by price and inventory headwinds. The company’s strategy is increasingly defined by global expansion, pipeline acceleration, and a deliberate push into biosimilars and new indications, setting the stage for long-term growth. Raised guidance and visible momentum in core brands counterbalance near-term pricing and channel noise, with the Horizon Therapeutics acquisition poised to amplify Amgen’s innovation platform.
Summary
- Volume-Driven Growth Outpaces Pricing Drag: Core franchises and new launches are capturing global patient demand, offsetting headwinds in price and inventory.
- Pipeline and Biosimilars Execution Accelerates: Registration-enabling studies and new biosimilar launches reinforce Amgen’s innovation and market access strategy.
- Strategic M&A and International Expansion: The Horizon deal and Asia-Pacific momentum strengthen Amgen’s long-term growth foundation.
Business Overview
Amgen is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines for serious illnesses. The company generates revenue from branded biologics, biosimilars, and specialty pharmaceuticals across general medicine (e.g., cardiovascular, bone health), inflammation, oncology, and hematology. Key revenue drivers include established brands like Repatha (cholesterol), Prolia (bone health), Otezla (psoriasis), and a growing biosimilars portfolio. Amgen’s business model leverages global scale, R&D investment, and manufacturing expertise to expand its therapeutic footprint and address unmet medical needs.
Performance Analysis
Amgen’s Q1 results were defined by a 14% surge in product volume, reflecting broad-based demand across geographies and franchises. General medicine, led by Repatha, Prolia, and Avenity, delivered double-digit growth, while hematology-oncology brands like Kyprolis and Blincyto set new sales records. International markets, especially Asia-Pacific, posted standout 47% volume growth, demonstrating successful global expansion strategies.
However, headline revenue was muted by a 5% decline in net selling price, a 3% negative impact from sales deductions, lower inventory levels, and a 2% FX headwind. Biosimilars revenue was pressured by price and inventory dynamics, particularly in oncology, but management highlighted a strategic shift toward new launches and medical benefit biosimilars. R&D investment climbed 12%, supporting late-stage pipeline advancement and innovation. Free cash flow was temporarily lower due to timing and elevated capital expenditures for new manufacturing capacity, but is expected to rebound over the year.
- Volume Expansion Outpaces Revenue: 14% volume growth was the key driver, with 13% revenue growth in general medicine and 21% in hematology-oncology offsetting pricing and inventory impacts.
- International and Asia-Pacific Strength: 22% volume growth outside the U.S. and 47% in Asia-Pacific highlight Amgen’s global reach and demographic tailwinds.
- Biosimilars and New Launches: Amgevita’s U.S. debut and Bekemvi’s European approval anchor a pipeline of biosimilar launches, with inventory-driven Q1 sales expected to normalize in Q2.
Net-net, Amgen’s performance reflects robust underlying demand, with temporary headwinds in price and inventory masking the scale of operational momentum. The company’s raised guidance signals management confidence in sustained growth for the remainder of 2023.
Executive Commentary
"I'll begin by calling your attention to the 14% volume growth we delivered in the first quarter. It illustrates two points worth keeping in mind... we're seeing that the demand for medicines is resilient despite the current macroeconomic challenges."
Bob Bradway, Chairman and Chief Executive Officer
"We are raising our 2023 revenue guidance to $26.2 to $27.3 billion... This reflects our confidence in the underlying business and the improving overall market conditions for our patients to access our medicines."
Peter Griffith, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Global Expansion and Demographic Tailwinds
Amgen’s international strategy is delivering, with Asia-Pacific volume up 47% and broader ex-U.S. growth at 22%. Penetration in aging populations, particularly Japan and China, is fueling demand for core brands like Prolia and Repatha. This positions Amgen to capitalize on demographic shifts and healthcare access improvements globally.
2. Pipeline Acceleration and R&D Commitment
R&D spend rose 12%, enabling late-stage trials for potential first-in-class assets in cardiology (Opaciran), inflammation (rocatinlamab), and oncology (bemerituzumab, tarlatumab). AI-driven discovery and trial optimization, a dry lab approach, is shortening cycle times and improving candidate quality, signaling a step-change in Amgen’s innovation engine.
3. Biosimilars as a Growth Lever
Amgen is doubling down on biosimilars, aiming to more than double 2021 sales by 2030 through first-wave launches and expansion into medical benefit biosimilars. The Amgevita Humira biosimilar launch was front-loaded by inventory, but management expects gradual demand build and sees continued attractive returns in the segment.
4. Capital Allocation and M&A Discipline
The Horizon Therapeutics acquisition is a transformative bet, adding first-in-class rare disease assets and a complementary pipeline. Meanwhile, near-peak capital expenditures for new U.S. manufacturing plants will taper, supporting long-term margin and cash flow improvement. Dividend increases and measured buybacks reinforce shareholder return priorities.
5. Commercial Execution and Market Access
Amgen is aggressively expanding primary care reach, especially for Repatha and Otezla, to address large, underpenetrated patient pools. Formulary wins and contracting are balancing price concessions with volume gains, while new product launches (Tezspire, Tavneos) are being supported by targeted physician education and self-administration options.
Key Considerations
This quarter’s results reflect a business in transition, balancing short-term headwinds with long-term opportunity across geographies, platforms, and indications.
Key Considerations:
- Inventory and Channel Dynamics: Temporary inventory workdowns and buy-in patterns, especially in biosimilars and Enbrel, created near-term revenue noise but are expected to normalize through 2023.
- Pricing Pressures Remain: Net selling price declined across several franchises, but management expects price erosion to slow and be offset by volume and access wins.
- Pipeline Readouts on Deck: Multiple late-stage data releases are expected in the second half, including for Tezspire (asthma and other indications), tarlatumab (oncology), and obesity programs (AMG-133, AMG-786).
- Horizon Integration Potential: The pending acquisition is expected to enhance Amgen’s rare disease and specialty portfolio, with commercial and global scale synergies.
Risks
Key risks include continued pricing pressure, especially in biosimilars and legacy brands, and competitive threats in core therapeutic classes (e.g., PCSK9, oncology). Inventory volatility and channel dynamics can obscure underlying demand trends quarter to quarter. Regulatory delays or integration challenges with the Horizon deal could disrupt strategic momentum. Pipeline execution risk remains, particularly for new mechanisms and indications.
Forward Outlook
For Q2 2023, Amgen guided to:
- Sequential free cash flow growth and stable 50% operating margin
- Cost of sales as a percentage of product sales between 16% and 17%
For full-year 2023, management raised guidance:
- Revenue of $26.2 to $27.3 billion
- Non-GAAP EPS of $17.60 to $18.70
Management highlighted:
- Solid portfolio volume growth consistent with Q1 trends
- Mid-single-digit price declines, offset by expanding access and international growth
Takeaways
Amgen’s Q1 results reinforce a strategic pivot to volume-driven, globally diversified growth, underpinned by innovation and operational discipline.
- Volume Resilience: Underlying demand for Amgen’s portfolio is robust, with global and new launch momentum offsetting pricing and inventory headwinds.
- Pipeline and Platform Leverage: Accelerated R&D and AI-enabled discovery are expanding Amgen’s addressable market and pipeline visibility.
- Horizon and Biosimilars as Catalysts: Successful integration and execution in these areas will be critical for sustaining multi-year growth and margin expansion.
Conclusion
Amgen’s first quarter marks a clear inflection toward global, volume-led growth, with innovation and disciplined execution at the core. Raised guidance and visible pipeline catalysts position the company to weather near-term pricing and channel volatility while building a defensible, diversified growth platform.
Industry Read-Through
Amgen’s results highlight the sector-wide shift from price-driven to volume-driven growth, with global expansion and biosimilars as key levers. R&D productivity, AI adoption, and capital deployment discipline are increasingly separating leaders from laggards in biopharma. The normalization of inventory and channel dynamics seen at Amgen may foreshadow similar trends for peers with large legacy franchises or biosimilar exposure. Strategic M&A and pipeline diversification remain critical as pricing pressure persists and payers demand value. Investors should watch for pipeline execution, integration outcomes, and the pace of international growth as key signals for the sector’s next phase.